BAY2757556 (Larotrectinib, Vitrakvi)
20289
Phase 2 small_molecule completed
Quick answer
BAY2757556 (Larotrectinib, Vitrakvi) for Solid Tumors Harboring NTRK Fusion is a Phase 2 program (small_molecule) at Bayer HealthCare AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer HealthCare AG
- Indication
- Solid Tumors Harboring NTRK Fusion
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed